Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma

Trial Profile

Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma

Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs RG 4733 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 May 2016 Time frame for primary endpoints changed.
    • 06 May 2016 Status changed from active, no longer recruiting to discontinued as it was administratively completed.
    • 23 Sep 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top